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The development of strains of herpes simplex virus (HSV) resistant to drugs has been reported among the immunocompromised
patients. Thus, there is a need to develop new therapeutic agents for HSV infections. We evaluated the anti-HSV activity of Bidens
pilosa (B. pilosa), a tropical weed, in tissue culture cells and a mouse model. B. pilosa extract showed potent virucidal activity. It
inhibited plaque formation and suppressed virus yield in Vero and RAW 264.7 cells infected with HSV-1 and HSV-2. Both the
binding of virus to host cells and penetration of virus into cells were also blocked by B. pilosa. Furthermore, B. pilosa was eﬀective
against thymidine kinase-deﬁcient and phosphonoacetate-resistant HSV-1 strains. B. pilosa treatment increased the survival rate
of HSV-infected mice and limited the development of skin lesions. Our results indicate that B. pilosa has anti-HSV activity and is
thus a potentially useful medical plant for treatment of HSV infection.
1.Introduction
Herpessimplexvirustypes1and2(HSV-1andHSV-2)cause
infections worldwide with an estimated 60–95% of adults
infected at least by one of them [1]. HSV is transmitted
through direct contact of the infected secretions and results
in common biological features of herpes viruses, including
latency and reactivation [2]. HSV causes a variety of
illnesses ranging from asymptomatic infection to fulminant
disseminated diseases, such as labial herpes, keratitis, genital
herpes, and encephalitis. Several forms of disseminated
HSV infection are encountered in patients with reduced
cell-mediated immunity such as bone marrow transplant
recipients and patients with acquired immunodeﬁciency
syndrome. Acyclovir (ACV) and other nucleoside derivatives
have been approved for treatment of HSV infections [1].
However, the increasing clinical application of this type
of antiviral agents has resulted in the emergence of drug-
resistant herpesvirus strains [3, 4]. In addition, the lack of
an eﬀective vaccine and the moderate-to-high toxicity of
the available synthetic antiherpes compounds emphasize the
need to discover and develop new alternative agents with
ad i ﬀerent mode of action for the management of HSV
infection.
Herbs are potential sources of useful medicinal com-
pounds. Bidens pilosa Linn. var. radiata is a tropical weed
widely present in the tropical and subtropical regions. This
plant was originally found in tropical America and later
introduced into thePaciﬁcregion and partsofAsiaincluding
Miyako Island, Okinawa, Japan. The whole plant or its aerial
parts is used in various folk medicines and as a popular
ingredient in herbal tea for its anti-inﬂammatory, antiseptic,
liver-protective, blood-pressure lowering, and hypoglycemic
eﬀects [5–11]. Although diverse bioactivities have been
identiﬁed in B. pilosa, its antiviral activity has not attracted
attentionsofar.Inaneﬀorttodiscovernovelantiviralagents,
B pilosa was investigated for its anti-HSV activities in tissue
culture cells and in a mouse model.2 Evidence-Based Complementary and Alternative Medicine
2.MaterialsandMethods
2.1. Reagents. B. pilosa Linn. var. radiata was grown from
seeds and harvested from January to July on Miyako Island,
Okinawa Prefecture, Japan. The harvested aerial parts were
washed twice with water, cut into pieces, and then steamed.
OnehundredkilogramsofdriedB.pilosawereboiledin1800
litre of water for 2h. The suspension obtained was treated
with the enzyme cellulosine, ﬁltered and concentrated.
Finally, B. pilosa extract was dried by spraydrier giving 40kg
of a brownish powder. This dried powder was provided by
Musashino Research Institute for Immunity Co., Ltd. (Oki-
nawa, Japan). ACV and rutin were purchased from Sigma-
Aldrich (St Louis, MO, USA). Phosphonoacetate and caﬀeic
acid were from Wako Pure Chemical Industries (Osaka,
Japan). NG-nitro-L-arginine methyl ester hydrochloride (L-
NAME)wasfromDojindoLaboratories(Kumamoto,Japan).
2.2. Cells and Viruses. African green monkey kidney Vero
cellsand murine macrophagestransformedwiththeAbelson
leukemia virus RAW 264.7 were propagated in Eagle’s Min-
imum Essential Medium and Dulbecco’s modiﬁed Eagle’s
Mediumsupplementedwithantibioticsand10%fetalbovine
serum, respectively. The cells were grown at 37◦Ci na
humidiﬁed atmosphere with 5% CO2.
HSV-1strainsHF[12]and7401H[13],andHSV-2strain
Savage were used. 7401H-derived thymidine kinase-deﬁcient
(TK−) HSV-1 [14] and phosphonoacetate-resistant (APr)
HSV-1 [15] were also used. The viruses were propagated in
Vero cells. The virus titer was determined by the plaque assay
and expressed as plaque-forming units (PFUs) per mL; virus
stocks were stored at −80◦C until use.
2.3. Cytotoxicity Assay. Vero cells and RAW 264.7 cells
were seeded at 1 × 104 cells per well in 96-well plates and
grown at 37◦C for 24h. Thereafter, the cells were incubated
with various concentrations of B. pilosa extract for 72h
at 37◦C. Cellular viability was assayed by measuring the
mitochondrial-dependent conversion of the water-soluble
tetrazolium (WST)-8 (Nacalai Tesque, Kyoto, Japan) to a
colored formazan product.
2.4. Virucidal Assay. The direct eﬀects of B. pilosa extract,
caﬀeic acid, and rutin on infection of HSV-1 strain HF
and HSV-2 strain Savage were evaluated. The concentrated
virus suspension (1.2 × 106 PFU/mL) was incubated with
an equal volume of Eagle’s Minimum Essential Medium
containing diﬀerent concentrations of B. pilosa extract (250,
500, 1000, and 2000μg/mL) at 37◦C for 1h. The infectious
virus remaining in the samples was diluted by 100-fold.
This dilution essentially eliminated the potential eﬀect of
the remaining extract on subsequent binding events. One
hundred microliters of the mixed suspensions were then
added to subconﬂuent monolayers of Vero cells at 4◦C. After
1h incubation for virus adsorption, the cell monolayers were
washed carefully twice with phosphate buﬀered saline (PBS),
and the residual virus infectivity was determined by plaque
assay following the procedures described below. The eﬀect of
B. pilosa extract on virus infectivity was calculated.
2.5. Antiviral Assay Using Plaque Reduction Assay. The anti-
viral activity of B. pilosa against HSV-1 and HSV-2 was
evaluated by the plaque reduction assay. Vero cells were
seeded onto 6-well culture plates at a density of 3 × 105 cells
per mL and incubated for 24h. The medium was then dis-
carded and the cell monolayer was infected with a virus sus-
pension to yield 100 plaques per well in the presence of var-
ious concentrations of B. pilosa extract (125, 250, 500, 1000,
and 2000μg/mL), ACV (3.1, 6.3, 12.5, 25, and 50μg/mL),
or phosphonoacetate (6.3, 12.5, 25, 50, and 100μg/mL).
The virus was allowed to be adsorbed for 1h at 4◦C, then
the cells were washed twice with PBS and overlaid with
an overlay medium containing 0.5% of methylcellulose and
dilutions of B. pilosa extract. The plate was further incubated
for a time period corresponding to four cycles of multipli-
cation of HSV (72h) [16]. Later, the overlay medium was
removed, and the infected cell monolayer was ﬁxed with
100%methanol.ThevirusplaquesformedonVerocellswere
stained with 0.2% crystal violet in 50% methanol.
In order to determine the mode of antiviral action of
B. pilosa extract, various concentrations of the extract were
added at diﬀerent periods of infection. Conﬂuent monolay-
ers were incubated with plain or extract-containing medium
for 1h before viral challenge at 37◦C( e ﬀect of cell pre-
treatment), during viral adsorption at 4◦Cf o r1h( e ﬀect on
adsorption),for1hat37◦Ctoallowviralinternalizationinto
cells (eﬀect on penetration), and during cultivation at 37◦C
(eﬀect on replication). After 72h, the number of plaques of
extract-treated cells was compared with untreated controls.
All untreated controls were incubated with culture medium
instead of the extract.
2.6. Virus Yield Reduction Assay. Vero and RAW 264.7 cell
monolayers were infected with the HSV-1-HF and HSV-2-
Savage strains. After 1h of adsorption at 4◦C, they were
washed twice with PBS and incubated at 37◦Ci nam e d i u m
containing 1000μg/mL B. pilosa extract. Twenty-four to 72h
postinfection, the medium was harvested into tubes. The
i n f e c t e dc e l lm o n o l a y e r sw e r ew a s h e dt w i c ew i t hP B Sa n d
subjected to three cycle of freeze-thawing. Virus yields in the
medium and cells were determined separately by the plaque
assay.
2.7. Reverse Transcriptase-PCR (RT-PCR). Total cellular
RNA from cells was extracted with Trizol (Invitrogen,
Carlsbad, CA, USA) according to the protocol provided by
the manufacturer. First-strand cDNA was synthesized from
1μg total cellular RNA using an RNA-PCR kit (Takara
Bio Inc., Otsu, Japan) with random primers. The primers
used were 5 -TCATTGTACTCTGAGGGCTGACACA-3 
(forward) and 5 -GCCTTCAACACCAAGGTTGTCTGCA-
3  (reverse) for murine inducible NO synthase (iNOS),
and 5 -GTGGGGCGCCCCAGGCACCA-3  (forward) and
5 -CTCCTTAATGTCACGCACGATTTC-3  (reverse) for β-
actin. The length of RT-PCR was 25 cycles for iNOS and
28 cycles for β-actin. The PCR products were fractionated
on 2% agarose gels and visualized by ethidium bromide
staining.Evidence-Based Complementary and Alternative Medicine 3
2.8. Measurement of Nitric Oxide (NO). Nitrite, the stable
end product of NO, was measured by the colorimetric assay.
Brieﬂy, the medium was removed from individual wells and
treated with Griess reagent (1% sulphanilamide and 0.1%
naphtylethylene diamine dihydrochloride in 2% H3PO4)f o r
10min at room temperature. The optical density of the
samples was obtained using an automated microplate reader
at 550nm. A standard curve using a standard solution of
NaNO2 in culture medium was employed to calculate the
nitrite concentration.
2.9. Eﬃcacy of B. pilosa Extract in a Cutaneous Mouse HSV-1
Infection Model. The right mid-ﬂank of each C57Bl/6 mouse
was chipped and depilated with a chemical depilatory hair
remover. The mice were randomly divided into four groups
each comprising 6 mice. Mice of the ﬁrst group, the control
group, were infected but received no treatment. Those of
the second group, the extract-treatment group, were infected
and treated with the B. pilosa extract (see below). The third
group was the extract-pretreatment group. An initial oral
dose of the B. pilosa extract was administered at day 7
before infection, followed by continuous administration of
the extract (see below). The ﬁnal fourth group was the
ACV-treatment group. In this group, mice were infected and
then treated with ACV. To induce infection, the naked skin
was scratched using a 26-guage needle, and 10μLo fH S V -
1 (7401H strain) suspension of 1 × 106 PFU was applied
to the scratched area, as described previously [13]. B. pilosa
extract (1g/kg per dose) or ACV (5mg/kg per dose) was
administered orally by gavage twice daily at 1h after HSV-1
inoculation and for 18 successive days after viral infection.
Oral administration of B. pilosa also commenced at day 7
prior to viral inoculation and continued thereafter for 18
days in the extract-pretreatment group.
The appearance of skin lesions was continuously
observed daily and scored as follows: 0, no lesion; 2, vesicles
in local region; 4, erosion and/or ulceration in the local
r e g i o n ;6 ,m i l dz o s t e r i f o r ml e s i o n ;8 ,m o d e r a t ez o s t e r i f o r m
lesion; 9, severe zosteriform; 10, death. The infected mice
were held at least for 18 days after infection. The toxicity of
B. pilosa extract was assessed in the treated mice by the loss
of body weight compared with the control group. The mice
were weighed once a week. This experiment was performed
according to the Guidelines for Animal Experimentation of
the University of the Ryukyus and approved by the Animal
Care and Use Committee of the University of the Ryukyus.
3. Results
3.1. Cytotoxicities of B. pilosa in Vero and RAW 264.7 Cells.
First, the concentration that did not aﬀect cell viability that
could be used in subsequent assays was determined. For
this purpose, the WST-8 assay was employed to determine
the cytotoxic eﬀect of B. pilosa extract in Vero and RAW
264.7 cells (Figure 1(a)). Subconﬂuent monolayers of Vero
cells treated with B. pilosa at concentrations ≤2000μg/mL
did not show any cytotoxic eﬀects. Moreover, B. pilosa
was also nontoxic against RAW 264.7 cells at ≤2000μg/mL
(Figure 1(a)). Microscopic examination of cell monolayers
after 72h of incubation with B. pilosa at 2000μg/mL
showed no changes in cell morphology compared with the
control (data not shown). Therefore, B. pilosa was used at
concentrations ≤2000μg/mL in subsequent studies.
3.2. Virucidal Eﬀect of B. pilosa Extract on HSV-1 and HSV-
2 Infectivity. The virucidal eﬀect of B. pilosa was evaluated
by incubating the extract with HSV-1 and HSV-2. As shown
in Figure 1(b), B. pilosa reduced infectivity of HSV-1 strain
HF and HSV-2 strain Savage depending on the dosage level.
These results indicate that B. pilosa directly inactivated the
viruses with potent virucidal eﬀects against HSV-1 and HSV-
2.
3.3. Virucidal Activity of Selected Constituents. Six caﬀeic
acid derivatives (neochlorogenic acid, chlorogenic acid, 4-
O-caﬀeoylquinic acid, 3,4-di-O-caﬀeoylquinic acid, 3,5-di-
O-caﬀeoylquinic acid, and 4,5-di-O-caﬀeoylquinic acid) and
7 ﬂavonoids (rutin, quercetin, quercetin derivative, hyperin,
isoquercitrin,centaurein,andjacein)havebeenisolatedfrom
B. pilosa [17]. The potential viral inactivation eﬀect of caﬀeic
acid and rutin was determined against HSV-1. Caﬀeic acid,
but not rutin, exhibited a concentration-dependent virucidal
eﬀect (Figure 2).
3.4. Eﬀect of B. pilosa Extract in Inhibiting Plaque Formation.
The plaque reduction assay demonstrated that B. pilosa
extractinhibitedplaqueformationofHSV-1andHSV-2,and
this eﬀect was dose-dependent (Figure 3(a)). Furthermore,
the number and size of plaques decreased in the presence
of B. pilosa extract (Figure 3(b)). To conﬁrm that B. pilosa
inhibits virus growth, both cell-associated and extracellular
viruses were separately titrated by the plaque assay. HSV-1-
and HSV-2-infected cells were treated with B. pilosa for 24h
as described in Section 2. Under these conditions, a time-
dependent reduction in the yield of both cell-associated and
extracellular viruses was observed at 1000μg/mL of B. pilosa
(Figure 3(c)).
3.5. Activity of B. pilosa Extract against Wild-Type and Drug-
Resistant HSV-1 Strains. The antiviral activities of B. pilosa
against HSV-1 TK−,A P r, and wild-type 7401H strains were
examined to evaluate its anti-HSV-1 modes of action. As
shown in Figures 4(a) and 4(b),T K
− and APr strains
were resistant to ACV and phosphonoacetate, respectively.
However, the susceptibility of TK− and APr strains to B.
pilosa extract was similar to that of the wild-type strain
(Figure 4(c)).
3.6. Eﬀects of B. pilosa Extract on RAW 264.7 Cells. Although
thehostdefensemechanismiscomplex,macrophagesarekey
participants in the innate immune system response to the
invasion of pathogenic organisms. We therefore investigated
the antiviral eﬀects of B. pilosa extract in macrophages.
Conﬂuent monolayers of RAW 264.7 murine macrophage
cells were inoculated with HSV-1, washed out, and then
incubated with or without B. pilosa extract. After 24–72h
of infection, virus yields in the medium and cells were
determinedseparatelybytheplaqueassay.Atime-dependent4 Evidence-Based Complementary and Alternative Medicine
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After 1h incubation for virus adsorption, the prescription was washed out and cells were overlaid with an overlay medium containing the
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reduction in the yield of both cell-associated and extra-
cellular viruses was observed at 1000μg/mL B. pilosa
(Figure 5(a)).
Previous work indicated that an NO-mediated antiviral
mechanism may be operative in HSV-1-infected RAW 264.7
cells [18]. To establish that iNOS is induced in RAW 264.7
cells after infection, we analyzed the expression of iNOS
mRNA. B. pilosa extract induced iNOS mRNA expression in
a dose-dependent manner (Figure 5(b)). In the next series
experiments, an inhibitor of NOS was used to determine if
NO contributed to the inhibition of HSV-1 replication in
RAW 264.7 cells. After inoculation of RAW 264.7 cells with
HSV-1, the monolayers were treated with B. pilosa extract
in the presence or absence of the competitive inhibitor, L-
NAME. As shown in Figure 5(c), B. pilosa extract stimulated
the production of NO from RAW 264.7 cells in a time-
dependent manner. The addition of L-NAME to the medium
decreasedtheproductionofNO.However,L-NAMEfailedto
reduce the ability of RAW 264.7 cells treated with B. pilosa
to inhibit HSV-1 replication. These data suggest that NO-
mediated antiviral mechanisms do not seem operative in B.
pilosa-treated macrophages.
3.7. Time of Addition Studies. The inhibitory eﬀect of B.
pilosa extract was determined following its addition at
diﬀerent time intervals relative to virus infection. The results
showed that various concentrations of B. pilosa extract
added at 3h prior to virus infection and then being washed
out before the infection did not have antiviral activity
(Figure 6(a)). In contrast, the concurrent addition of B.6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Activity of ACV (a), phosphonoacetate (b), and B. pilosa extract (c) on the plaque formation of wild-type and resistant strains of
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pilosa extract with virus and washing the extract out at 1h
postinfection inhibited HSV-2 infection. In a single cycle
of virus replication, inhibition of virus infectivity was most
pronounced when B. pilosa was added concurrently with
virus infection, with continued presence of the B. pilosa
extract for the entire 18h period of infection. The inhibition
of plaque formation was observed when B. pilosa extract was
added at between 1 and 6h after virus infection. Delaying
the time of adding extract failed to signiﬁcantly decrease its
antiviral activity. In other words, the inhibitory eﬀect of B.
pilosa extract on the virus was persistent even when added
6hafterinfection. These resultsindicate thatB.pilosaextract
aﬀected viral adsorption, penetration, and replication.
In order to investigate the stage at which the B. pilosa
aﬀected the viral life cycle, experiments on the time of
addition were performed. (1) Monolayers were incubated
with the extract for 1h, washed with PBS, and challenged
with HSV (pretreatment). (2) After adsorption for 1h at
4◦C in the presence of extract, the cells were washed with
PBS and incubated with culture medium (adsorption). (3)
After adsorption, the medium was replaced with extract-
containing medium, the cells were washed with PBS, and
overlaid with an overlay medium (penetration). (4) After
penetration, the cells were washed with PBS, overlaid with
anoverlaymediumcontainingextract,andfurtherincubated
for 72h (replication). (5) The extract was added at 1h prior
to virus infection and remained present for the entire 72h
period of infection (entire period). The results showed that
the extract added at 1h prior to virus infection and then
washed out did not have antiviral activity (Figure 6(b)),Evidence-Based Complementary and Alternative Medicine 7
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similar to the data shown in Figure 6(a). In contrast, adding
extract before infection, with continued presence of the
extract for the entire 72h period of infection, resulted
in marked reduction of plaque formation, and this eﬀect
was dose-dependent. Its presence during viral adsorption,
penetration, and replication reduced plaque formation in a
dose-dependent manner (Figure 6(b)).
3.8. Eﬃcacy of B. pilosa Extract in a Cutaneous Mouse HSV-
1 Infection Model. The anti-HSV-1 activity of B. pilosa was
evaluated in the skin of HSV-1-infected mice. Previously,
we found that B. pilosa extract was well tolerated and
no side eﬀect was observed when four-week-old rats were
administered orally with B. pilosa extract at 2g/kg, once
a day, for 14 days (data not shown). Therefore, the B.
pilosa extract was administered orally every 12h for 18 days
after infection at 1g/kg per dose. Treatment with B. pilosa
extract delayed the development and progression of skin
lesions compared with the control. The anti-HSV-1 eﬃcacy
of B. pilosa was further analyzed by pretreatment of infected8 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Time of addition studies. (a) Mode of inhibitory eﬀect of B. pilosa extract against HSV-2 during diﬀerent periods of the viral
replication cycle. Vero cells were treated with 500, 1000, and 2000μg/mL B. pilosa extract. The extract was added prior to infection (−3h),
during adsorption (0h), or after infection (1, 2, 4, and 6h). The prescription was either washed out at indicated times or continuously
remained present for the entire 18h period of infection (left panel). The antiviral activity was determined in Vero cells by the plaque
reduction assay. After 18h, the number of plaques of extract-treated cells was compared with untreated controls. Data are % of control
and represent mean ± SD of triplicate cultures. (b) Vero cells were incubated with plain or extract-containing medium for 1h before HSV-1
challenge (pretreatment), during viral adsorption for 1h (adsorption), for 1h to allow viral internalization into cells (penetration), and
during cultivation (replication). After 72h, the number of plaques of extract-treated cells was compared with untreated controls. Data are
presented as % of control.
animals. In these experiments, mice received B. pilosa twice
daily for 7 days before HSV-1 infection, and treatment was
continued till 18 days after HSV-1 infection. Pretreatment
with B. pilosa delayed the development and progression of
skin lesions similar to ACV treatment. Two mice of the
control group died during the 18-day treatment period, but
all mice treated with B. pilosa or ACV after HSV-1 infection,
and those pretreated with B. pilosa, were still alive at 18
days after infection (Figure 7(b)). Toxicity studies of B. pilosa
extract in infected mice based on frequent measurement of
bodyweightsindicatedthatB.pilosahasnotoxiceﬀects(data
not shown).Evidence-Based Complementary and Alternative Medicine 9
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Figure 7: Eﬀects of B. pilosa extract on mice cutaneously infected with HSV-1. Six mice in each group were infected. Extract (1g/kg per
dose) and ACV (5mg/kg per dose) were orally applied twice daily before or after infection. Mice were monitored everyday for development
of skin lesions (a) and survival (b). , control (water treatment); , B. pilosa extractpretreatment;, B. pilosa treatment; ×, ACV treatment.
4. Discussion
Studies had shown that the extracts and several constituents
of B. pilosa exhibit various clinical eﬀects, whereas only
one report has shown that hot water extract of B. pilosa
had antiviral activity [19]. The present study demonstrated
the antiviral activity of B. pilosa e x t r a c ta g a i n s tH S V - 1
and HSV-2 both in vitro and in vivo. In vitro, B. pilosa
extract did not prevent Vero cells from HSV-1 and HSV-
2 infection in the pretreatment assay, but showed virucidal
eﬀect against HSV-1 and HSV-2. The time of addition
experiments suggested multiple targets of activity—B. pilosa
extract inhibited virus adsorption to cells and aﬀected some
intracellular steps of viral replication. Our results imply
that B. pilosa seems to inhibit HSV biological synthesis and
directly inactivate the viruses, and blocking their adsorption
to the cells in vitro. Furthermore, the virucidal eﬀect of
one constituent, caﬀeic acid, was determined against HSV-
1 in vitro. This phenomenon may be explained by the
nature of plant extracts, which typically contain many
compounds with diﬀerent physicochemical characteristics.
The extracts can thus be accepted as being the sum of dif-
ferent pharmacologically active substances, in certain cases
even acting antagonistically or synergistically, demonstrating
polyvalent action by interfering with diﬀerent steps of the
virus replication cycle.
Our results showed that both the wild and resistant
strains of HSV-1 were sensitive to the extract. Since the
mechanismsofactionofACVandphosphonoacetatearewell
understood, it is therefore conceivable that the mechanism
of action of the extract against these resistant viral strains
is diﬀerent from that of the antiviral action of ACV and
phosphonoacetate. Further investigation of the mechanism
of action is needed.
NO is being recognized as an important component of
thehostresponsetoinfection.SinceNOhasantiviralactivity
[18] and RAW 264.7 cells can be stimulated to overproduce
NO by B. pilosa extract, we examined whether NO-mediated
antiviral mechanism could explain the inhibitory eﬀects
of B. pilosa extract on HSV-1 replication in RAW 264.7
cells. Indeed, RAW 264.7 cells were permissive to HSV-1
replication. However, the inhibitor of NOS, L-NAME, did
not reduce the ability of RAW 264.7 cells to suppress HSV-
1r e p l i c a t i o nb yB. pilosa extract. These results suggest that
NO does not contribute to the antiviral activity of B. pilosa
extract.
We employed an HSV-infected C57Bl/6 mouse model
suitable for screening and evaluating anti-HSV agents. Cu-
taneous inoculation of HSV-1 strain resulted in the develop-
ment of skin lesions in all mice and death of some mice. We
used 10mg/kg/day of ACV and 2g/kg/day of B. pilosa extract
for oral administration to mice in this HSV-1 infection
m o d e l .T h em i c et r e a t e dw i t hB. pilosa extract before and
after infection showed better survival rate compared to the
virus control group. Furthermore, B. pilosa extract delayed
the development and progression of skin lesion. Further-
more, treatment with the extract before infection showed
more eﬀective therapeutic anti-HSV-1 eﬃcacy than treat-
ment after infection. The results suggest the beneﬁcial eﬀects
of this extract in preventing reactivation of HSV.
T h ep r o t e c t i v ee ﬀect of B. pilosa in mice may be related
to an immunomodulatory activity as well as a direct antiviral
eﬀect. The extract of B. pilosa and two bioactive ﬂavonoids
from B. pilosa were reported to stimulate the expression of
interferon-γ, a potent cytokine [20]. Considered together,
this plant extract is potentially useful therapeutically against
HSV infection.
The utilization of medicinal plant extracts as drugs,
medicines,orsupplementsbasedontheirbiologicalactivities
examined scientiﬁcally allows their use in health care ser-
vices. Therefore, B. pilosa extract could be clinically useful10 Evidence-Based Complementary and Alternative Medicine
whenusedprophylacticallyortherapeuticallyasananti-HSV
medicine and could be eﬀective against ACV-resistant vari-
ants encountered during ACV therapy. The mechanism of
action and clinical study of this extract need further inves-
tigations.
5. Conclusions
Hot water extract of B. pilosa showed activity against HSV-1
and HSV-1 both in vitro and in vivo. The present study has
demonstrated the potential clinical application of B. pilosa.
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